^
Association details:
| Biomarker: | MAP2K2 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
Compared to the effects of wild type MEK2, cells expressing resistance-associated MEK2 mutations were less sensitive to both RAF (dabrafenib; Fig. 2C) and MEK (trametinib; Fig. 2D) inhibition.
DOI:
10.1158/2159-8290.CD-13-0617
